Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

The French government has taken a small stake in Sanofi's consumer healthcare business Opella, following political backlash about the pharmaceutical company's deal with a US private equity firm.